Chart Analysis
NOX Daily Timeframe Chart as of 26 May 2026
Noxopharm (ASX: NOX) Reports 200-Fold TLR8 Immune Amplification in Human Tissue — Preclinical Data Opens New Immuno-Oncology Application for Sofra™ Platform
Noxopharm's proprietary Sofra™ oligonucleotides boosted the activity of an existing cancer immunotherapy drug by more than 200-fold in human skin biopsies — but the effect dropped to approximately 3-fold when tested in a living animal model. That gap between ex vivo and in vivo results is the central question facing the company's newest immuno-oncology program, which targets Toll-like receptor 8 (TLR8) amplification as a way to enhance standard-of-care chemotherapy and radiotherapy. The technology is protected by a granted US patent and represents a combinatorial approach — amplifying existing TLR8 agonists rather than replacing them. Cancer model testing in humanised mice is planned for the coming months. No IND has been filed, no clinical trial timeline exists, and the pathway from preclinical data to an approved therapy typically spans 7–15 years with a failure rate exceeding 90%.
The Data — What Was Measured and What It Means
Two experimental results were reported:
In ex vivo human skin biopsies, a Sofra TLR8-potentiating oligonucleotide combined with motolimod (a clinical-stage TLR8 agonist) produced more than 200-fold amplification of immune activation versus the agonist alone. The specific biomarker measured was not disclosed.
In transgenic mice expressing human TLR8, a systemically delivered Sofra oligonucleotide combined with R848 (a TLR7/8 agonist) produced approximately 3-fold amplification across three TLR8-responsive biomarkers in the spleen. The biomarkers were not named.
The 67-fold reduction in effect size from ex vivo to in vivo is expected — isolated tissue receives direct compound exposure, while whole-body systems introduce pharmacokinetics, distribution, metabolism, and immune regulation that moderate the response. But the magnitude of the drop is notable, and clinical outcomes in cancer patients cannot be predicted from either result. Critically, no tumour growth inhibition or anti-tumour efficacy data has been presented — these were immune activation assays, not cancer models.
| Detail | Value |
|---|---|
| Ex Vivo Result | >200-fold TLR8 amplification (human skin biopsy + motolimod) |
| In Vivo Result | ~3-fold TLR8 amplification (transgenic mouse spleen + R848) |
| Biomarkers Measured | Not disclosed (ex vivo: 1 unnamed; in vivo: 3 unnamed) |
| IP Protection | Granted US patent |
| Cancer Model Data | None — testing planned "in the months ahead" |
| IND Status | Not filed for TLR8 oncology program |
| Stage | Preclinical |
Where TLR8 Fits in Noxopharm's Pipeline
The TLR8 program adds a third application vertical to Noxopharm's Sofra™ platform alongside SOF-SKN (autoimmune/dermatology — HERACLES trial, first human doses July 2025) and SOF-VAC (mRNA vaccine enhancement). Separately, the Chroma™ platform includes CRO-67 (pancreatic cancer) and the IONIC program combining Veyonda® with Bristol Myers Squibb's Opdivo for solid tumours — the FDA approved the Veyonda IND in May 2026, enabling IONIC-1 to commence.
Five active programs across two platforms on TTM revenue of A$2.82 million and losses of A$4.88 million. The company raised A$2.5 million in May 2025. The cost of humanised mouse studies, cancer model testing, and eventual IND-enabling work for TLR8 has not been disclosed.
Risks & Considerations
The data is preclinical and contains no cancer-relevant efficacy endpoints. The >200-fold ex vivo result measures immune activation in isolated human tissue, not anti-tumour activity. The ~3-fold in vivo result comes from spleen biomarkers in transgenic mice, not from tumour-bearing models. Until the compounds are tested in cancer models showing tumour growth inhibition or survival benefit, the "cancer-fighting potential" referenced in the announcement title remains a hypothesis.
The biomarker identity problem compounds the uncertainty. Neither the ex vivo biomarker nor the three in vivo biomarkers were named. Without knowing what was measured, the clinical relevance of the fold-changes cannot be independently assessed by analysts or the scientific community.
Competitive context is also relevant: motolimod — the very agonist used in Noxopharm's ex vivo study — failed a Phase 2 clinical trial in head and neck cancer when developed by VentiRx/Celgene. Multiple pharmaceutical companies (Merck, Novartis, and others) are pursuing TLR8 modulators for cancer. Noxopharm's amplifier approach is differentiated but entirely unproven in oncology.
The resource allocation question is unavoidable. Five programs across two platforms with A$2.82 million in TTM revenue, A$4.88 million in losses, and a A$2.5 million raise completed over a year ago. Further capital is likely required, and spreading limited resources across this many programs increases execution risk for all of them.
Key Dates & Timeline
| Date | Event |
|---|---|
| July 2025 | HERACLES autoimmune trial first human doses (SOF-SKN) |
| May 2026 | FDA approves Veyonda IND (IONIC-1 trial to commence) |
| 26 May 2026 | TLR8 preclinical data announced; share price moved +43.3% |
| Coming months | Humanised TLR8 mouse cancer model testing planned |
| TBC | IONIC-1 clinical trial commencement (Veyonda + Opdivo) |
Price Data
- Previous Close: $0.060
- Close Price (26 May 2026): $0.086
- Change (26 May 2026): +43.3%
- 52-Week Range: $0.043 – $0.135
Notable Price Levels
-
$0.135 — 52-week high from H2 2025 (HERACLES first human doses, SOF-SKN data). The stock retraced ~68% from this peak to the $0.043 low. At ~57% above the current close, the stock has recovered less than half of its prior decline despite the TLR8 data — the market is not yet pricing this catalyst at the same level as the 2025 Sofra/Chroma catalyst flow.
-
$0.095 — intraday high on announcement day, rejected 9.5% to close at $0.086. Selling pressure emerged just below the $0.097–$0.099 overhead supply cluster from the late 2025 decline, suggesting the stock encountered resistance from prior holders before reaching the higher consolidation zone.
-
$0.060 — undisturbed close and the $0.055–$0.065 pre-announcement base. A retracement here would fully unwind the TLR8 premium. The stock had recovered to this level from the $0.043 52-week low over the preceding weeks.
-
$0.043 — 52-week low (~A$13M market cap). A return here would reverse both the TLR8 catalyst and the Q2 recovery, pricing NOX at its most pessimistic 12-month valuation.
Summary
Noxopharm's Sofra™ oligonucleotides amplified TLR8-driven immune activation by more than 200-fold in ex vivo human skin biopsies and approximately 3-fold in a transgenic mouse model — preclinical results that open a new immuno-oncology application for the platform. The stock moved +43.3% to $0.086 on 26 May 2026, though it faded from a $0.095 intraday high. The technology targets TLR8 amplification as a combinatorial approach to enhance existing cancer therapies, protected by a granted US patent. No cancer model efficacy data exists, no IND has been filed, and the biomarkers measured in both studies were not disclosed. Noxopharm is advancing five programs across two platforms on TTM losses of A$4.88 million, with cancer model testing in humanised mice planned for the coming months.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.
